Categories: News

Beyond Medical Technologies Inc. Announces Management Changes and New Appointment of Daniel Liu as Chief Executive Officer and Director

Vancouver, British Columbia–(Newsfile Corp. – February 3, 2025) – Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM) (OTC Pink: DOCKF) (“Beyond Medical” or the “Company“) is pleased to announce that it has appointed Daniel Liu as Chief Executive Officer and as a director of the Company. Mr. Liu replaces Kal Malhi in these roles, following Mr. Malhi’s resignation as Chief Executive Officer and as a director, effective January 30, 2025.

Mr Malhi leaves Beyond Medical to pursue other ventures but will remain available to consult for the Company as required. The Company would like to thank Mr. Malhi for his service and wishes him the best in his future endeavors.

On behalf of the Board of Directors

“Daniel Liu” Chief Executive Officer
Email: danzliu94@gmail.com
https://beyond-md.ca/

Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the accuracy or adequacy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239500

Staff

Recent Posts

Olympian Gabby Thomas Draws Crowd at Wellness Event with BetterWay(TM) Blood Testing at H-E-B SoCo

Guests had an opportunity to meet Gabby Thomas, win health-focused prizes, and learn simple ways…

10 hours ago

UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026

CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…

19 hours ago

Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis

Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…

22 hours ago

GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained

Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…

22 hours ago

MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs

Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…

22 hours ago